$5.50
▲ +$0.14
(+2.61%)
Vol 3.3M
2
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$726.5M
ROE
-92.5%
D/E
0.00
Beta
1.14
52W
$1–$6
Wall Street Consensus
16 analysts · Apr 20264
Strong Buy
11
Buy
1
Hold
0
Sell
0
Strong Sell
93.8%
Buy Rating
Price Chart
Similar Stocks
Earnings
Beat rate: 40.0%
Next Report
May 11, 2026
EPS Estimate: $-0.30
| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Mar 2026 | $-0.30 | — | — |
| Dec 2025 | $-0.32 | $-0.28 | +$0.04 |
| Sep 2025 | $-0.35 | $-0.37 | $-0.02 |
| Jun 2025 | $-0.37 | $-0.34 | +$0.03 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Net Income | -$34.8M | -$48.6M | -$54.4M | -$49.2M | -$54.9M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -70.2% | -70.0% | -70.0% | -70.0% | -92.5% | -92.5% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 5.67 | 5.67 | 5.67 | 5.67 | 4.42 | 4.42 |
Key Ratios
ROA (TTM)
-72.4%
P/B
1.9
EPS (TTM)
$-1.38
CF/Share
$-1.87
52W High
$5.66
52W Low
$1.29
$1.29
52-Week Range
$5.66
Financial Health
Free Cash Flow
-$52.4M
Net Debt
-$112.5M
Cash
$139.4M
Total Debt
$26.9M
As of Sep 30, 2025
How does ANNX compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
ANNX valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
—
▼
0%
below
peers
(12.9)
vs Peers
vs Industry
Overvalued
P/B ratio
1.9
▼
24%
below
peers
(2.5)
vs Peers
vs Industry
Pricier
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
ANNX profitability vs Biotechnology peers
ROE
-92.5%
▼
37%
below
peers
(-67.3%)
vs Peers
vs Industry
Weak
Net margin
—
▼
0%
below
peers
(-286.8%)
vs Peers
vs Industry
Top tier
Gross margin
—
▼
0%
below
peers
(78.6%)
vs Peers
vs Industry
In line
ROA
-72.4%
▼
55%
below
peers
(-46.7%)
vs Peers
vs Industry
Weak
ANNX financial health vs Biotechnology peers
D/E ratio
0.0
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
Low debt
Current ratio
4.4
▼
0%
below
peers
(4.4)
vs Peers
vs Industry
In line
Beta
1.1
▲
18%
above
peers
(1.0)
vs Peers
vs Industry
More volatile
ANNX fundamentals radar
ANNX
Peer median
Industry
ANNX profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
ANNX vs peers: key metrics
Insider Activity
NeutralBuys
0
Sells
0
CARSON WILLIAM H.
Director · Mar 10
8000 shs
LEW JENNIFER
Chief Financial Officer · Mar 02
5565 shs
DANANBERG JAMIE
Officer · Mar 02
5820 shs
OVERDORF MICHAEL
Officer · Mar 02
4339 shs
YEDNOCK TED
Officer · Mar 02
5566 shs
ARTIS DEAN RICHARD PH.D.
Officer · Mar 02
5894 shs
LEW JENNIFER
Chief Financial Officer · Feb 19
62500 shs
DANANBERG JAMIE
Officer · Feb 19
56250 shs
OVERDORF MICHAEL
Officer · Feb 19
62500 shs
YEDNOCK TED
Officer · Feb 19
62500 shs
Last 90 days
Top Holders
Top 5: 38.54%FMR, LLC
8.54%
$51.1M
Redmile Group, LLC
8.40%
$50.3M
BVF Inc.
7.63%
$45.6M
Blackrock Inc.
7.49%
$44.8M
Vanguard Group Inc
6.48%
$38.8M
As of Dec 31, 2025
Latest News
No related news yet